drugset
drugset / Trial / NCT00474669

A Phase I Study of Intraperitoneal Hyperthermic Docetaxel

NCT00474669 ↗

Phase 1 Completed 30 enrolled University of Louisville James Graham Brown Cancer Center · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to assess the maximum tolerated dose of docetaxel administered intraperitoneally with heat at the time of second-look surgery in patients with stage II/III ovarian carcinoma.

Timeline

Start
2007-06
Primary completion
2009-12
Completion
2009-12

Publications

  • Results 1 - R. Bruno, D. Hille, L. Thomas, A. Riva and L.B. Sheiner. Population Pharmacokinetics / Pharmacodynamics (PK/PD) of Docetaxel (Taxotere) in Phase II studies. Proc. ASCO, 14, 457, 1995. 2 - S. L. Beal, A.J. Boeckman and L.B. Sheiner. NONMEM version 4. User's Guide Part I to VI. University of California at San Francisco, San Francisco, 1988 - 1992.

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — Other

Indications

ovarian carcinoma